Osteoporosis Management for the Orthopaedic Surgeon: Closing the Care Gap

Visual Element: An interactive graph showing the "Fracture Cascade" - how a wrist fracture at 50 leads to a vertebral fracture at 60 and a hip fracture at 70, with the associated mortality risk increasing at each step.

Orthopaedic surgeons are technically brilliant. We can nail a femur through a keyhole incision, reconstruct a shattered pelvis, and replace arthritic joints with robotic precision. Yet, we have a collective blind spot in our surgical education. We are historically terrible at managing the underlying disease that keeps us in business: Osteoporosis.

A patient presenting with a fragility fracture—defined classically as a fracture resulting from a fall from standing height or less—has established osteoporosis. This is a clinical fact, not just a radiological diagnosis. Yet, retrospective audits and global registry data consistently show that up to 80% of these patients are discharged from orthopaedic wards without any investigation, secondary prevention, or treatment for their failing bone health.

This is the "Care Gap." In modern orthopaedic surgery training, mastering the tension band wire is no longer enough; you must also master bone metabolism. Whether you are navigating your daily trauma list or deep in fellowship exam preparation (ABOS, FRCS, or FRACS), understanding osteoporosis management is non-negotiable. It is our responsibility as the primary treating clinicians to close this gap.

The Scope of the Problem: The Silent Epidemic

Osteoporosis is a silent, progressive killer. The true cost of the disease is only realized when the mechanical structural integrity of the skeleton fails.

• The Sentinel Event: A Distal Radius Fracture (Colles' fracture) in a post-menopausal 55-year-old woman is the loudest warning sign we get. It is the strongest predictor of a future vertebral or hip fracture. Treating the wrist and ignoring the bone density is akin to treating a myocardial infarction with pain relief and ignoring the cholesterol.
• The Mortality Rate: The 1-year mortality of a neck of femur (NOF) fracture in the elderly population sits stubbornly between 20-30%. This mortality rate rivals or exceeds many common malignancies.
• The Re-fracture Rate and "Imminent Risk": Without pharmacological intervention, the risk of a second major osteoporotic fracture is exceptionally high. Crucially, this risk is not linear—it peaks in the first 12 to 24 months following the initial fracture. This critical window is known as the "Imminent Risk" period. Delaying treatment guarantees a missed opportunity.

Diagnosis: Moving Beyond the T-Score

In surgical education, we are often taught to rely solely on the DEXA scan (Dual-Energy X-ray Absorptiometry). While DEXA is the gold standard for quantifying bone mineral density (BMD), an over-reliance on numbers can obscure the clinical picture.

1. DEXA (Dual-Energy X-ray Absorptiometry)

DEXA provides an areal bone density measurement (g/cm²), traditionally measured at the lumbar spine and total hip/femoral neck.

• T-Score: Compares the patient's bone density to the peak bone mass of a healthy, sex-matched 30-year-old.
  • Normal: > -1.0
  • Osteopenia (Low Bone Mass): -1.0 to -2.5
  • Osteoporosis: < -2.5
  • Severe Osteoporosis: < -2.5 with a history of a fragility fracture.
• Z-Score: Compares the patient's bone density to an age, sex, and ethnicity-matched control. This is exceptionally useful in younger patients (pre-menopausal women or men <50). A Z-score of < -2.0 should immediately trigger a rigorous hunt for secondary causes of bone loss.

2. The Clinical Diagnosis

Crucial Concept for Fellowship Exams: If a patient has sustained a low-trauma fracture of a major bone (hip, clinical spine, proximal humerus, distal radius, or pelvis), they have "Clinical Osteoporosis" regardless of what the DEXA scanner says. A 75-year-old patient with a T-score of -1.5 who sustains a neck of femur fracture from a simple mechanical fall has osteoporosis and unequivocally requires pharmacological treatment. Do not withhold therapy waiting for a scan that will not change your management.

3. FRAX (Fracture Risk Assessment Tool)

Developed by the WHO, FRAX calculates the 10-year probability of a major osteoporotic fracture and a hip fracture. It integrates clinical risk factors (age, BMI, prior fracture, parental hip fracture, current smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, and alcohol intake) with or without femoral neck BMD.

• Exam Tip: In many jurisdictions, a 10-year major osteoporotic fracture risk of >20%, or a hip fracture risk of >3%, is the threshold for initiating treatment.

4. Secondary Workup: The Orthopaedic Minimum

Before starting any antiresorptive, you must rule out secondary causes and ensure the patient is replete in essential building blocks. The basic orthopaedic workup includes:

• Serum Calcium, Phosphate, and Albumin (Corrected Calcium)
• 25-OH Vitamin D
• Renal function (eGFR is critical for medication selection)
• Thyroid Function Tests (TFTs)
• Parathyroid Hormone (PTH)
• In specific cases: Serum Protein Electrophoresis (SPEP) / Urine Protein Electrophoresis (UPEP) to rule out Multiple Myeloma, or Celiac serology (TTG).

Pharmacotherapy: The Surgeon's Guide to Bone Health

You don't need to be an endocrinologist, but as a modern orthopaedic surgeon, you need to know the basics to initiate therapy, prescribe the right drug upon discharge, and answer viva questions during your fellowship exam preparation.

Foundation: Calcium and Vitamin D

These are not "treatments" for osteoporosis; they are prerequisites. They do not significantly reduce fracture risk on their own but are necessary for bone-active drugs to work.

• Calcium: 1000-1200mg daily (preferably through diet; supplement only the deficit).
• Vitamin D3 (Cholecalciferol): 800-1000 IU daily for maintenance.

Class 1: Antiresorptives (The Brakes)

These drugs fundamentally inhibit osteoclast activity, slowing down the rate of bone resorption and allowing secondary mineralization of existing osteons.

Bisphosphonates (Alendronate, Risedronate, Zoledronic Acid)

First-line therapy for the vast majority of patients.

• Mechanism: These are pyrophosphate analogues that bind aggressively to hydroxyapatite crystals in areas of active bone remodeling. When osteoclasts resorb the bone, they ingest the bisphosphonate, which disrupts their intracellular pathways (specifically the mevalonate pathway), leading to osteoclast apoptosis (cell death).
• Administration Routes:
  • Oral (Alendronate/Risedronate): Usually weekly or monthly. They have notoriously poor GI absorption (<1%). Patients must take them on an empty stomach with a full glass of water and remain upright for 30-60 minutes. GI upset and esophageal irritation are the main reasons for non-compliance.
  • Intravenous (Zoledronic Acid/Aclasta/Zometa): A once-yearly 5mg infusion. Overcomes all GI issues and guarantees 100% compliance for the year.
• The Timing Debate (The HORIZON Trial): Classic orthopaedic dogma dictated delaying bisphosphonates for 2-6 weeks post-fracture out of fear that inhibiting osteoclasts would impair fracture callus remodeling and lead to non-union. The landmark HORIZON Recurrent Fracture Trial showed that giving Zoledronic acid within 90 days of a hip fracture reduced mortality by 28% and clinical fractures by 35%. Current consensus dictates that the massive clinical benefit of ensuring the patient receives the infusion before discharge far outweighs any theoretical, largely unproven risk of delayed fracture union.
• Duration: Typically 3-5 years for IV, and 5 years for oral, followed by a reassessment for a "Drug Holiday" to mitigate the risk of atypical femur fractures.

Denosumab (Prolia)

• Mechanism: A fully human monoclonal antibody that binds to RANK-Ligand (RANKL). By blocking RANKL from binding to the RANK receptor on osteoclast precursors, it profoundly halts osteoclast formation, function, and survival.
• Administration: A 60mg subcutaneous injection every 6 months. It is not cleared by the kidneys, making it the drug of choice in patients with severe renal impairment (eGFR < 35).
• The Trap: Rebound Phenomenon: This is a critical piece of surgical education. Denosumab's effect wears off precisely at 6 months. If a dose is delayed or missed, there is a massive rebound increase in osteoclast activity. Bone turnover skyrockets, leading to rapid bone loss and a very high risk of multiple spontaneous vertebral compression fractures.
  • Rule: You cannot just "stop" Denosumab. If a patient wishes to cease therapy, you must transition them to a bisphosphonate (like a Zoledronic acid infusion) to lock in the bone density gains and prevent the rebound cascade.

Class 2: Anabolic Agents (The Builders)

These drugs stimulate osteoblasts to actively build new bone. They are powerful, expensive, and generally reserved for severe osteoporosis (T-score < -3.0), failure of antiresorptive therapy, or patients presenting with multiple severe fragility fractures.

Teriparatide (Forteo) & Abaloparatide (Tymlos)

• Mechanism: Recombinant human Parathyroid Hormone (PTH 1-34) analogues. While continuous high PTH (like in hyperparathyroidism) destroys bone, pulsatile, intermittent, low-dose PTH potently stimulates osteoblast activity over osteoclasts.
• Administration: Daily subcutaneous self-injection for a maximum lifetime duration of 18-24 months. Once stopped, the new bone will be rapidly lost unless immediately followed by an antiresorptive agent (bisphosphonate or Denosumab).
• Contraindications: Absolute contraindications include a history of skeletal radiation therapy, Paget's disease of bone, unexplained elevated alkaline phosphatase, or skeletal malignancies due to a theoretical (rat-model) risk of osteosarcoma.

Romosozumab (Evenity)

The newest weapon in the arsenal, highly relevant for current fellowship exam preparation.

• Mechanism: A monoclonal antibody that inhibits Sclerostin. Sclerostin is a protein produced by osteocytes that normally puts the "brakes" on bone formation (inhibits the Wnt signaling pathway).
• The Dual Effect: By blocking sclerostin, Romosozumab releases the brake, causing a massive surge in bone formation by osteoblasts, while simultaneously causing a mild decrease in bone resorption. It builds bone faster than any other agent.
• Administration: Monthly injections for 12 months, followed by an antiresorptive.
• Warning (Boxed Warning): Clinical trials (like the ARCH trial) showed a small but statistically significant increase in major adverse cardiovascular events (MACE). It should be avoided in patients who have had a myocardial infarction or stroke within the preceding year.

Establishing a Fracture Liaison Service (FLS)

You cannot manage the osteoporosis epidemic alone from a busy fracture clinic. The internationally recognized gold standard of care is the Fracture Liaison Service (FLS) model.

An FLS ensures that every patient presenting with a fragility fracture is systematically captured, assessed, and treated.

• The Coordinator: The heart of the FLS is usually a dedicated clinical nurse specialist or allied health professional. They actively identify patients from ED presentations, orthopaedic ward admissions, and fracture clinic rosters.
• The 4 i's Protocol:
  1. Identify: Case-finding all patients over 50 with a new fragility fracture.
  2. Investigate: Organizing DEXA scans, FRAX calculations, and the baseline bone-health blood panel (Calcium, Vit D, PTH, eGFR).
  3. Initiate: Recommending or directly prescribing appropriate first-line pharmacological therapy (often a Zoledronic acid infusion on the ward before discharge) and falls prevention strategies.
  4. Integrate: Ensuring seamless communication with the patient's General Practitioner (Primary Care Physician) for long-term monitoring, medication compliance, and scheduling of future DEXA scans.

Visual Element: FLS Workflow diagram (Identify -> Investigate -> Initiate -> Integrate) demonstrating the closed-loop system that prevents patients from falling through the cracks.

Complications to Consent For: The Orthopaedic Relevance

When prescribing these medications, or when taking a history from a trauma patient, you must be acutely aware of the rare but famous complications associated with long-term antiresorptive use.

1. Medication-Related Osteonecrosis of the Jaw (MRONJ)

• Risk: Very rare in standard osteoporosis dosing (approx. 1 in 10,000 to 100,000 patient-years). The risk is significantly higher in oncology patients receiving high-dose monthly IV bisphosphonates for skeletal metastases.
• Prevention: Always ask about planned invasive dental work or extractions before initiating therapy. Routine cleaning and fillings are safe.

2. Atypical Femoral Fractures (AFF)

This is the complication orthopaedic surgeons fear most, and a favorite topic in FRCS and ABOS exams. AFFs occur due to severe suppression of bone turnover over many years, preventing the repair of physiological micro-damage. The bone becomes dense but brittle (like chalk).

• Criteria (ASBMR): They occur in the subtrochanteric region or femoral shaft. They are often transverse or short oblique, associated with a lateral cortical beak or flare, and occur with minimal to no trauma.
• The Prodrome: 70% of patients will complain of prodromal aching thigh pain for weeks or months before the fracture completes.
• Management: If a patient is on long-term bisphosphonates (usually >5 years), you must be vigilant.

Conclusion

As modern orthopaedic surgeons, we must expand our definition of surgical "success." A perfectly reduced and fixed intertrochanteric fracture is a profound clinical failure if the patient returns to your emergency department 6 months later with a contralateral hip fracture simply because we ignored their failing bone density.

The initial fracture is the alarm bell. It is our duty to answer it. By integrating secondary fracture prevention into our routine trauma workflows, advocating for FLS programs, and understanding the pharmacology of bone health, we can save lives, preserve independence, and truly heal our patients.

We fix the bone. Now we must own the bone.

Osteoporosis Treatment Algorithm

Download our quick-reference decision tree for selecting the right pharmacological agent based on renal function, fracture severity, and patient profile.